+

WO2005075990A3 - Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2) - Google Patents

Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2) Download PDF

Info

Publication number
WO2005075990A3
WO2005075990A3 PCT/EP2005/000679 EP2005000679W WO2005075990A3 WO 2005075990 A3 WO2005075990 A3 WO 2005075990A3 EP 2005000679 W EP2005000679 W EP 2005000679W WO 2005075990 A3 WO2005075990 A3 WO 2005075990A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
nr4a2
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/000679
Other languages
French (fr)
Other versions
WO2005075990A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005075990A2 publication Critical patent/WO2005075990A2/en
Publication of WO2005075990A3 publication Critical patent/WO2005075990A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human NR4A2 which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle-skeleton disorders, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle-skeleton disorders, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NR4A2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/000679 2004-02-07 2005-01-25 Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2) WO2005075990A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002760 2004-02-07
EP04002760.9 2004-02-07

Publications (2)

Publication Number Publication Date
WO2005075990A2 WO2005075990A2 (en) 2005-08-18
WO2005075990A3 true WO2005075990A3 (en) 2005-10-06

Family

ID=34833577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/000679 WO2005075990A2 (en) 2004-02-07 2005-01-25 Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)

Country Status (1)

Country Link
WO (1) WO2005075990A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183601A1 (en) * 2014-05-28 2015-12-03 Scripps Health Predictive analysis for myocardial infarction

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070254A1 (en) * 2000-03-21 2001-09-27 Smithkline Beecham P.L.C. Use of human not1 and not1a orphan receptors
WO2003012040A2 (en) * 2001-07-27 2003-02-13 Baylor College Of Medecine Mutant nurr1 gene in parkinson's disease
WO2003037260A2 (en) * 2001-10-30 2003-05-08 Biogen, Inc. Methods and compositions for treating parkinson's disease
WO2004045369A2 (en) * 2002-11-14 2004-06-03 Nura, Inc. Nuclear receptor-based diagnostic, therapeutic, and screening methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070254A1 (en) * 2000-03-21 2001-09-27 Smithkline Beecham P.L.C. Use of human not1 and not1a orphan receptors
WO2003012040A2 (en) * 2001-07-27 2003-02-13 Baylor College Of Medecine Mutant nurr1 gene in parkinson's disease
WO2003037260A2 (en) * 2001-10-30 2003-05-08 Biogen, Inc. Methods and compositions for treating parkinson's disease
WO2004045369A2 (en) * 2002-11-14 2004-06-03 Nura, Inc. Nuclear receptor-based diagnostic, therapeutic, and screening methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTINEZ-GONZALEZ J ET AL: "The NR4A subfamily of nuclear receptors: new early genes regulated by growth factors in vascular cells", CARDIOVASCULAR RESEARCH, vol. 65, no. 3, 15 February 2005 (2005-02-15), pages 609 - 618, XP004722369, ISSN: 0008-6363 *

Also Published As

Publication number Publication date
WO2005075990A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005075990A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2006005460A3 (en) Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 2, group e, member 1 (nr2e1)
WO2005114210A8 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载